Because our previous experiments demonstrated that HDAC inhibition potentiates the cytotoxicity of thiazolidinediones against a range of breast cancer cell lines, we were curious as to whether similar synergistic effects are also experienced by non-malignant cells. Here, HDAC9 is linked to breast carcinoma.